Authors
Latest:
Comprehensive Treatment Advances Care for Patients With Early-Stage Breast CancerAdvances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.
Latest:
Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive MyelofibrosisJoseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Latest:
Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple MyelomaDickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.
Latest:
Dr Zaha on the Risk of Cardiovascular Toxicity in Patients With Lung CancerVlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.
Latest:
Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in LymphomaIra Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.
Latest:
Dr Blackwood on the Significance of Early Breast Cancer ScreeningsM. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.
Latest:
Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular CancerJennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.
Latest:
Dietrich and Shiller Dive Into the Importance of Oncology Reflex TestingDrs Dietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex testing.
Latest:
UChicago Medicine Among the First to Offer Histotripsy for Liver TumorsThe University of Chicago Medicine treats patients with histotripsy, a technology that uses ultrasound energy to destroy liver tumors.
Latest:
Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIsAmanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.
Latest:
Dr Kishtagari on JAK Inhibitor Selection for Myelofibrosis in the Community SettingAshwin Kishtagari, MD, discusses the selection process of JAK inhibitors for patients with myelofibrosis being treated in a community setting.
Latest:
Dr Shu on Advances in Adjuvant Therapy For Early-Stage NSCLCCatherine Ann Shu, MD, discusses key therapeutic advances in the adjuvant setting for patients with early-stage non–small cell lung cancer.
Latest:
Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast CancerMeghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract CancerMojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.
Latest:
Dr Massarelli on Using Selpercatinib and Pralsetinib in Treating Advanced Non-Small Cell Lung CancerErminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.
Latest:
Dr Chudgar on Defining Resectability in NSCLCNeel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.
Latest:
Dr Jha on Community Accrual to the ECLIPSE Trial in Prostate CancerGautam Jha, MD, discusses collaborative efforts between community and academic oncologists to accrue patients to the ECLIPSE trial.
Latest:
Dr. Mark on Questions Regarding Sequencing in Multiple MyelomaTomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.
Latest:
Drs Gerber and Nwachukwu on the Importance of Streamlining Clinical Research in Cancer CareDavid Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
Dr. Venkat on Unmet Needs in Ovarian CancerPuja S. Venkat, MD, discusses unmet needs in ovarian cancer.
Latest:
BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLCExpert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.
Latest:
Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPCBilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.
Latest:
Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETsNitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.
Latest:
Dr Nowakowski on Monitoring Epcoritamab-Associated ICANS and CRS in Follicular LymphomaGrzegorz S. Nowakowski, MD, discusses toxicity monitoring strategies for epcoritamab treatment in relapsed/refractory follicular lymphoma.
Latest:
Dr. Roque on the Importance of Biomarker Testing in Advanced Endometrial CancerDario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.
Latest:
Dr. Weiss on Selecting Optimal Radiation Therapy for Brain MetastasesStephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.
Latest:
Dr Huang on the Use of Neoadjuvant PARP Inhibitors in Advanced Ovarian CancerMarilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.
Latest:
Dr Imanirad on Toxicity Management for Encorafenib Plus Cetuximab in BRAF-Mutant mCRCIman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.
Latest:
Dr. Mahal on the Emerging Role of Epigenomics in Prostate CancerBrandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.
.jpg?fit=crop&auto=format)
